Global Antimicrobial Resistance and Use Surveillance System (GLASS)

T1Primary Institutionalvia glassRetrieved Apr 18, 2026View original source ↗

Grounds assessments

activeECDC will formally classify Candidozyma auris (formerly Candida auris) as endemic in ≥3 EU/EEA countries via a technical report, surveillance update, or risk assessment by 2026-10-17, formalizing the trajectory described in Medscape 2026-04-13 ("C auris Is Now Endemic in Europe. Can It Be Contained?") and CIDRAP 2025-09-11 ("Multidrug-resistant yeast cases rising rapidly in Europe, survey shows").60%activetetM-carrying N. gonorrhoeae prevalence in US surveillance reaches ≥30% by EOY 2026 OR ≥3 independent confirmed extensively drug-resistant (ceftriaxone+azithromycin+ciprofloxacin simultaneously resistant) N. gonorrhoeae transmission clusters documented in US/EU/AU during 2026, threatening the doxyPEP era and last-line cephalosporin therapy.60%activeCDC will publish a Morbidity and Mortality Weekly Report (MMWR) early release or health advisory specifically characterizing XDR Shigella (azithromycin + fluoroquinolone + 3GC resistant) geographic spread and treatment guidance within 60 days of the April 13 2026 emergence report (by June 12 2026), consistent with CDC's precedent of issuing MMWR early releases for novel drug-resistant Shigella phenotypes (2022-2023 ceftriaxone-resistant Shigella MMWR).60%expiredAt least one XDR Shigella case with genomic linkage to the US April 2026 emergence cluster will be confirmed in Australia, Canada, or Japan within 120 days (by August 13 2026), based on high-frequency MSM travel networks connecting these countries to the US, and the historical 2022-2023 pattern where drug-resistant Shigella reached high-income Pacific Rim countries within 8 months of initial US detection.40%expiredXDR Shigella (extensively drug-resistant, resistant to azithromycin + fluoroquinolones + 3GC) will establish sustained community transmission in at least 3 US states within 12 months of CDC's April 2026 emergence report, requiring updated CDC treatment guidance and triggering enhanced surveillance protocols.40%activeAt least one prospective cohort study will document ARG vertical transfer from mother to neonate as a measurable predictor of neonatal treatment outcomes, demonstrating that community AMR carriage surveillance systematically underestimates baseline population ARG burden40%activeCDC 2026 AR Threats Report (electronic release) will document that ≥3 of the 6 hospital-onset AMR pathogen groups tracked in the 2024 special report (CRAB, CRE, ESBL-Ent, MRSA, MDR-Pa, VRE) remain ≥10% above pre-pandemic 2019 baseline through 2024 surveillance data, confirming sustained post-COVID AMR backslide rather than recovery.70%

Evidence content

This evidence item came from a structured or high-volume payload, so the public page shows a compact preview rather than dumping raw records inline.

hosts: []
counts: {"cases":0,"deaths":0,"samples":0}
places: ["Sudan","Israel","Ukraine"]
country: Sudan
rawItem: {"url":"https://www.who.int/initiatives/glass","title":"Global Antimicrobial Resistance and Use Surveillance System (GLASS)","attributes":{"source":"dom-content","word_count":"1382"},"description":"Global Antimicrobial Resistance and Use Surveillance System (GLASS) Antimicrobial resistance (AMR) represents a major threat to human health with significant global economic and security implications. In 2015, WHO Member States unanimously approved a Global Action Plan to tackle AMR (GAP-AMR). The g"}
language: en

Technical metadataPipeline attribution for verification

Connector: glass
Payload kind: timeseries
Run ID: eda475c3-2449-43d4-b624-9d09e18a3374
Schema version: —

Assessment unavailable

This assessment could not be loaded right now because no recent cached snapshot is available.